SCHEMBL1608386

SCHEMBL1608386

CNc1ccc(-c2nc(-c3ccc(OC)cc3)no2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.70
NPC1 O15118 11/20 0.70
MAPT P10636 9/20 0.70
SMN1; SMN2 Q16637 5/20 0.70
NR1H4 Q96RI1 3/20 0.70
NPSR1 Q6W5P4 2/20 0.70
S1PR1 P21453 1/20 0.70
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
TP53 P04637 2/20 0.56
LMNA P02545 2/20 0.56
HPGD P15428 3/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
CASP3 P42574 1/20 0.56
PKM P14618 2/20 0.55
HSP90AA1 P07900 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16592612 0.89 RAB9A (0.72) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL22757148 0.84 NR1H4 (0.78) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL16592723 0.84 NR1H4 (0.83) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL16602947 0.84 NPC1 (0.83) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL6697420 0.83 NR1H4 (1.00) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL7291752 0.83 NR1H4 (1.00) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL12895918 0.82 RAB9A (0.76) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL16592531 0.81 RAB9A (0.74) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL29936657 0.81 RAB9A (0.74) RAB9ANPC1MAPTSMN1; SMN2NR1H4
SCHEMBL17056188 0.81 NPC1 (0.69) RAB9ANPC1MAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 RAB9A 4026/4885NPC1 129/4885MAPT 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.